Faculty, Staff and Student Publications

Publication Date

9-19-2022

Journal

Pharmaceutics

Abstract

RNA interference (RNAi) therapies have significant potential for the treatment of inflammatory bowel diseases (IBD). Although administering small interfering RNA (siRNA) via an oral route is desirable, various hurdles including physicochemical, mucus, and cellular uptake barriers of the gastrointestinal tract (GIT) impede both the delivery of siRNA to the target site and the action of siRNA drugs at the target site. In this review, we first discuss various physicochemical and biological barriers in the GI tract. Furthermore, we present recent strategies and the progress of oral siRNA delivery strategies to treat IBD. Finally, we consider the challenges faced in the use of these strategies and future directions of oral siRNA delivery strategies.

Keywords

oral drug delivery, siRNA, inflammatory bowel disease, gene delivery, nanomedicines, Immunotherapy

DOI

10.1126/sciadv.adf3887

PMID

36145716

PMCID

PMC10219598

PubMedCentral® Posted Date

November 2023

PubMedCentral® Full Text Version

Post-Print

Published Open-Access

yes

Download

Plum Print visual indicator of research metrics
PlumX Metrics
  • Citations
    • Citation Indexes: 62
  • Usage
    • Downloads: 11
    • Abstract Views: 3
  • Captures
    • Readers: 55
  • Mentions
    • News Mentions: 2
see details

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.